Launch of seventh stage of Lahekalda apartments development project (Tallinn, Estonia)
Lahekalda quarter 2025 eoy Lahekalda quarter 2025 Get the latest news delivered to your inbox Sign up for…
Novo Nordisk’s Record Pill Launch Meets a Cybersecurity Reality Check
The Danish drugmaker is living two parallel stories this quarter. One is about the Wayovy pill smashing prescription…
Launch of the second stage of Magnolijas residential project (Riga, Latvia)
Skrines 10 Skrines 10 visualisation Get the latest news delivered to your inbox Sign up for The Manila…
Novo Nordisk’s Oral GLP-1 Launch Beats Forecasts, Yet India Price War and Market Caution Check Ent
Novo Nordisk’s oral Wegovy crushes Q1 forecasts with $2.26B revenue, yet a fast-maturing India generics threat and CagriSema…
Novo Nordisk’s Oral Wegovy Surpasses $300 Million in Q1 as Global Launch Looms
Novo Nordisk’s oral Wegovy smashed Q1 sales forecasts at $330M, with 2M prescriptions. Global launch begins H2 2026…
Novo Nordisk’s Wegovy Pill Rewrites the Launch Playbook, but a One-Time Windfall Skews the Numbers
Oral Wegovy prescriptions top 2 million in Q1, sales nearly double estimates at $354M. Novo Nordisk raises guidance…
Wegovy maker Novo Nordisk boosted by successful weight loss pill launch
Wegovy maker Novo Nordisk said surging demand for its first weight loss pill has put it on track…
FDA Crackdown and Oral Ozempic Launch Set Stage for Earnings
Novo Nordisk enters a pivotal week with an FDA shortage-list victory, oral Ozempic rollout, and partnerships to capture…
Canadian Generic Launch and Q1 Results Loom
Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…
Novo Nordisk’s AI Bet and High-Dose Launch Face a Revenue Reality Check
Novo Nordisk shares surge on OpenAI partnership and buybacks, but Wall Street is cautious due to sales mix,…
Launch of the Pētersala residential project (Riga, Latvia)
Petersala visualisation 1 Petersala visualisation 1 Get the latest news delivered to your inbox Sign up for The…
Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model
Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain…